Bioactive Dairy Composition IgG Retention via pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing heat-stable bioactive immunoglobulin G (IgG) in dairy products are costly and inefficient, particularly for small to medium-scale manufacturers, as they often require high-pressure processing or result in the loss of casein and reduced nutritional value due to the removal of casein during processing.
Innovation Solution
A bioactive dairy composition is developed, comprising colostrum or milk powder, IgG, and a food-grade acid, heated to 60-150°C, maintaining a pH of 2.5-4.0 to retain 20-90% bioactive IgG levels, which can be used in ready-to-eat or ready-to-drink products, incorporating additional ingredients like lecithin and sweetening agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-pressure processing or casein removal methods are used to produce heat-stable bioactive IgG, then heat stability and IgG retention are improved, but manufacturing cost increases and nutritional value decreases
Solution Approach 1:
The patent applies parameter changes by adjusting pH to the isoelectric point (pH 4.6) during heat treatment, which prevents IgG denaturation and aggregation. This chemical parameter modification allows conventional thermal processing to maintain IgG stability without requiring expensive high-pressure equipment or casein removal steps, thereby resolving the contradiction between heat stability and manufacturing cost
Solution Approach 2:
The patent introduces pH adjustment as an intermediary mechanism to mediate between heat treatment and IgG stability. By controlling the pH environment during heating, the process enables thermal processing to preserve IgG activity without the need for costly alternative methods, thus reducing manufacturing complexity while maintaining reliability
2Manufacturing precision
If casein is removed during processing to retain IgG, then IgG purity is improved, but nutritional value and protein content decrease
Solution Approach 1:
The patent applies partial action by selectively precipitating only casein at its isoelectric point (pH 4.6) while leaving IgG in solution. This selective precipitation achieves sufficient IgG purification without complete casein removal, thereby maintaining the nutritional value and protein content of the final product while still achieving the desired IgG purity
Solution Approach 2:
The patent applies local quality by creating different pH conditions at different stages: pH adjustment to 4.6 during heat treatment for selective casein precipitation, followed by pH adjustment to 6.8 for IgG stabilization. This localized pH control enables selective separation of casein from IgG, achieving purification without compromising overall nutritional content
3Ease of manufacture
If conventional thermal processing is used, then manufacturing cost is reduced, but IgG activity is lost due to denaturation
Solution Approach 1:
The patent applies parameter changes by modifying the pH condition during thermal processing to the isoelectric point of casein (pH 4.6). This parameter modification prevents IgG denaturation and aggregation during heating, allowing conventional thermal processing equipment to be used while maintaining IgG activity, thus resolving the contradiction between manufacturing cost and IgG activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the production of cost-effective, heat-stable bioactive dairy products with retained IgG levels, enhancing nutritional value and commercial viability, suitable for a range of dairy products with extended shelf life.
Implementation Method 1
heated to 60-150°C to pasteurize the composition
Implementation Method 2
maintaining a pH of 2.5-4.0 to retain 20-90% bioactive IgG levels
Data Source
AI summary
A process for the preparation of a liquid or semi-liquid bioactive dairy composition containing 20-90% retained bioactive IgG, for use as an ingredient in a ready-to-eat (RTE) or ready-to-drink (RTD) food product, includes the steps of a) combining a bioactive powder containing a colostrum powder and/or milk powder containing whey proteins, and immunoglobulin G (IgG), wherein the ratio of whey protein: IgG in the bioactive powder is between 1.74:1 and 3.05:1; water and a food grade acid to form a bioactive dairy composition with a pH of 2.5-4.0, and b) heat treating the bioactive dairy composition to between 67-145° C. at ambient pressure.